{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:49:55Z","timestamp":1793317795059,"version":"4.5.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.blre.2022.100991","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T02:12:11Z","timestamp":1658196731000},"page":"100991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment"],"prefix":"10.1016","volume":"57","author":[{"given":"Yasmina","family":"Serroukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.blre.2022.100991_bb0005","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0015","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100991_bb0020","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1182\/blood-2018-99-120082","article-title":"Increased monocytic myeloid-derived suppressor cells in the marrow of relapsed\/refractory acute myeloid leukemia patients following induction chemotherapy","volume":"132","author":"Przespolewski","year":"2018","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.blre.2022.100991_bb0025","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0030","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"OncoImmunology."},{"issue":"13","key":"10.1016\/j.blre.2022.100991_bb0035","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3390\/jcm10132788","article-title":"Myeloid-derived suppressor cells and mesenchymal stem\/stromal cells in myeloid malignancies","volume":"10","author":"Kapor","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2022.100991_bb0040","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0045","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0055","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4049\/jimmunol.174.3.1269","article-title":"Bone marrow is a preferred Site for homeostatic proliferation of memory CD8 T cells","volume":"174","author":"Becker","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0060","first-page":"867","article-title":"Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory","volume":"25","author":"Feuerer","year":"2004","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.it.2005.04.011","article-title":"The bone marrow: a nest for migratory memory T cells","volume":"26","author":"Di Rosa","year":"2005","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2005.01.008","article-title":"Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells","volume":"22","author":"Mazo","year":"2005","journal-title":"Immunity."},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0080","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.V90.5.2103","article-title":"Bone marrow contains virus-specific cytotoxic T lymphocytes","volume":"90","author":"Slifka","year":"1997","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0085","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","article-title":"Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse","volume":"109","author":"Chen","year":"2006","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2022.100991_bb0090","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.4049\/jimmunol.0802212","article-title":"Central memory CD8 + T cells induce graft-versus-host disease and mediate graft-versus-leukemia","volume":"182","author":"Zheng","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2022.100991_bb0095","first-page":"184","article-title":"A T cell view of the bone marrow","volume":"7","author":"Bonomo","year":"2016","journal-title":"Front Immunol [Internet]"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0100","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood-2004-07-2856","article-title":"Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells","volume":"105","author":"Monteiro","year":"2005","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0105","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood.V84.8.2436.2436","article-title":"Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells","volume":"84","author":"Kaufman","year":"1994","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb0110","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb0115","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/pbc.25587","article-title":"Severe combined immunodeficiency (SCID) presenting with neonatal aplastic anemia","volume":"62","author":"Scott","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"7350","key":"10.1016\/j.blre.2022.100991_bb0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10160","article-title":"In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche","volume":"474","author":"Fujisaki","year":"2011","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic heterogeneity and clonal evolution in acute myeloid leukemia","volume":"28","author":"Romer-Seibert","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Br\u00fcck","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","article-title":"Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia","volume":"31","author":"Percival","year":"2017","journal-title":"Blood Rev"},{"issue":"18","key":"10.1016\/j.blre.2022.100991_bb0145","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0150","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/sj.leu.2402835","article-title":"Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia","volume":"17","author":"Panoskaltsis","year":"2003","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100991_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2021.11.003","article-title":"Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia","volume":"105","author":"Kenswil","year":"2022","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100991_bb0160","first-page":"64","article-title":"Kinetics of cytotoxic lymphocytes reconstitution after induction chemotherapy in elderly AML patients reveals progressive recovery of normal phenotypic and functional features in NK cells","volume":"8","author":"Rey","year":"2017","journal-title":"Front Immunol [Internet]"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0165","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell."},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0170","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2022.100991_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100786","article-title":"Metabolic regulation of the bone marrow microenvironment in leukemia","volume":"48","author":"Xu","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.16310","article-title":"Acute myeloid leukaemia and the immune system: implications for immunotherapy","volume":"188","author":"Barrett","year":"2020","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.blre.2022.100991_bb0185","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0190","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0195","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","article-title":"Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes","volume":"54","author":"Ehx","year":"2021","journal-title":"Immunity."},{"key":"10.1016\/j.blre.2022.100991_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid Leukemia: a focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol [Internet]"},{"issue":"21","key":"10.1016\/j.blre.2022.100991_bb0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0215","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: a novel salvage therapy in patients who Relapse after allogeneic stem-cell transplantation for acute myeloid Leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"Biomark Res"},{"issue":"17","key":"10.1016\/j.blre.2022.100991_bb0225","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","article-title":"T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment","volume":"8","author":"Schnorfeil","year":"2015","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100991_bb0235","series-title":"T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies","first-page":"28","author":"Janelle","year":"2021"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0240","doi-asserted-by":"crossref","first-page":"1930391","DOI":"10.1080\/2162402X.2021.1930391","article-title":"Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML","volume":"10","author":"Brauneck","year":"2021","journal-title":"Oncoimmunology."},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb0245","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2020.00276","article-title":"T-Cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies","author":"Janelle","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0250","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/cancers13061203","article-title":"Immunosuppressive cell subsets and factors in myeloid Leukemias","volume":"13","author":"Swatler","year":"2021","journal-title":"Cancers."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0255","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb0260","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ni.2713","article-title":"CD1d-lipid antigen recognition by the \u03b3\u03b4 TCR","volume":"14","author":"Uldrich","year":"2013","journal-title":"Nat Immunol"},{"issue":"6472","key":"10.1016\/j.blre.2022.100991_bb0265","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1126\/science.aav3900","article-title":"A class of \u03b3\u03b4 T cell receptors recognize the underside of the antigen-presenting molecule MR1","volume":"366","author":"Le Nours","year":"2019","journal-title":"Science."},{"key":"10.1016\/j.blre.2022.100991_bb0270","article-title":"\u03b3\u03b4 T Cells for leukemia immunotherapy","volume":"12","author":"de Barros","year":"2021","journal-title":"New and Expanding Trends Front Immunol"},{"issue":"22","key":"10.1016\/j.blre.2022.100991_bb0275","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.2020007592","article-title":"Diversity, localization, and (patho)physiology of mature lymphocyte populations in the bone marrow","volume":"137","author":"Sch\u00fcrch","year":"2021","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0280","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cyto.b.20115","article-title":"Flow cytometric assessment of autologous \u03b3\u03b4 T cells in patients with acute myeloid leukemia: Potential effector cells for immunotherapy?","volume":"70B","author":"Aswald","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"issue":"21","key":"10.1016\/j.blre.2022.100991_bb0285","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2019000682","article-title":"Impact of \u03b3\u03b4 T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"3","author":"Arruda","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100991_bb0290","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3389\/fimmu.2019.01997","article-title":"Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR Gamma Delta Cells 2 months after allogeneic stem cell transplantation","volume":"10","author":"Minculescu","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0295","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF01715050","article-title":"Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution","volume":"67","author":"Vidriales","year":"1993","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.blre.2022.100991_bb0300","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020459118","article-title":"High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome","volume":"118","author":"Chretien","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0305","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0310","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2249.2001.01692.x","article-title":"Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia","volume":"126","author":"Orleans-Lindsay","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0315","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.leu.2405040","article-title":"NK cell receptors and their ligands in leukemia","volume":"22","author":"Verheyden","year":"2008","journal-title":"Leukemia."},{"issue":"15","key":"10.1016\/j.blre.2022.100991_bb0325","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0330","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100991_bb0335","series-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"11","author":"Lamble","year":"2022"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-016-2153-5","article-title":"Bone marrow T-cell percentage: a novel prognostic indicator in acute myeloid leukemia","volume":"105","author":"Ismail","year":"2017","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0345","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pag\u00e8s","year":"2010","journal-title":"Oncogene."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the \u201cImmunoscore\u201d in the classification of malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0355","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0360","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity."},{"key":"10.1016\/j.blre.2022.100991_bb0365","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer [Internet]"},{"issue":"49","key":"10.1016\/j.blre.2022.100991_bb0370","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116427118","article-title":"Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes","volume":"118","author":"Ferraro","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"546","key":"10.1016\/j.blre.2022.100991_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.blre.2022.100991_bb0380","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0385","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/biomedicines6040110","article-title":"Dissecting the immune landscape of acute myeloid leukemia","volume":"6","author":"Davidson-Moncada","year":"2018","journal-title":"Biomedicines."},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0390","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.blre.2022.100991_bb0395","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0400","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100991_bb0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era?","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0410","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2022.100991_bb0415","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3389\/fimmu.2021.695051","article-title":"Novel immune cell-based therapies to eradicate high-risk acute Myeloid Leukemia","volume":"12","author":"Limongello","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101222","article-title":"Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?","volume":"33","author":"Bewersdorf","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2022.100991_bb0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14728222.2021.1937123","article-title":"Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations","volume":"25","author":"Tabana","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0430","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: Immune Checkpoint Inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100991_bb0435","first-page":"103164","article-title":"Immune evasion mechanisms in Acute Myeloid Leukemia; a focus on immune checkpoint pathways","volume":"18","author":"Taghiloo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0440","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjh.17125","article-title":"Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo","volume":"193","author":"Rastogi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100991_bb0445","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100991_bb0450","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.100991_bb0455","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","author":"Zeidan","year":"2022","journal-title":"Ann Hematol [Internet]"},{"issue":"10","key":"10.1016\/j.blre.2022.100991_bb0460","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100991_bb0465","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2019-122896","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100991_bb0470","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1038\/bcj.2014.14","article-title":"5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies","volume":"4","author":"Gang","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2022.100991_bb0475","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2021.650473","article-title":"Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter","volume":"11","author":"Kordella","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100991_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/418292","article-title":"5-azacytidine promotes an inhibitory T-Cell phenotype and impairs immune mediated antileukemic activity","volume":"2014","author":"St\u00fcbig","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0485","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label","volume":"9","author":"Daver","year":"2019","journal-title":"Phase II Study Cancer Discov"},{"key":"10.1016\/j.blre.2022.100991_bb0490","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0495","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2022.100991_bb0500","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021004583","article-title":"Single-cell Polyfunctional Proteomics of CD4 cells from patients with aml predicts responses to Anti-PD-1-based therapy","author":"Abbas","year":"2021","journal-title":"Blood Adv [Internet]"},{"key":"10.1016\/j.blre.2022.100991_bb0505","series-title":"Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML","author":"Daver","year":"2021"},{"key":"10.1016\/j.blre.2022.100991_bb0510","first-page":"1","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","author":"Daver","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100991_bb0515","first-page":"1555","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.blre.2022.100991_bb0520","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0525","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0530","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100991_bb0535","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood-2018-99-111539","article-title":"Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123 \u00d7 CD3 Bispecific Dart\u00ae Molecule, in patients with relapsed\/refractory acute myeloid Leukemia","volume":"132","author":"Rutella","year":"2018","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0540","first-page":"1172","article-title":"Evolving exhaustion of T cells during the course of the disease in AML can be abrogated By CD33 BiTE<sup>\u00ae<\/Sup> construct mediated cytotoxicity","volume":"138","author":"Kazerani Pasikhani","year":"2021","journal-title":"ASH"},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135945","article-title":"The broad Anti-AML activity of the CD33\/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk. mills K, editor","volume":"10","author":"Harrington","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.blre.2022.100991_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.002","article-title":"Cellular therapy for acute myeloid Leukemia \u2013 Current status and future prospects","volume":"37","author":"Hansrivijit","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2022.100991_bb0555","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.blre.2019.02.001","article-title":"Cellular immunotherapy for acute myeloid leukemia: How specific should it be?","volume":"35","author":"Lee","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0560","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100991_bb0565","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: How the Hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100991_bb0570","first-page":"4516","article-title":"Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk Leukemia and Lymphoma patients after HCT","volume":"130","author":"Williams","year":"2017","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0575","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.blre.2022.100991_bb0580","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0585","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell."},{"issue":"19","key":"10.1016\/j.blre.2022.100991_bb0590","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML)","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0595","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100991_bb0600","article-title":"Engineering T cells to survive and thrive in the hostile tumor microenvironment","volume":"21","author":"Kim","year":"2022","journal-title":"Curr Opin Biomed Eng"},{"key":"10.1016\/j.blre.2022.100991_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100695","article-title":"Revving the CAR - Combination strategies to enhance CAR T cell effectiveness","volume":"45","author":"Bansal","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0610","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-Based therapies with a focus on CAR NK cells: What Lies Beyond CAR-engineered T Cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0615","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.blre.2022.100991_bb0620","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0625","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytotherapy."},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0630","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical NK cells infused prior to allogeneic stem cell transplant for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0635","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1539617","article-title":"Acute myeloid leukemia and NK cells: two warriors confront each other","volume":"8","author":"Baraga\u00f1o Raneros","year":"2018","journal-title":"Oncoimmunology."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0640","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.blre.2014.08.002","article-title":"Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment","volume":"28","author":"Krakow","year":"2014","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0645","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0650","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100991_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683381","article-title":"Optimizing NK cell-based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment","volume":"12","author":"Kaweme","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb0660","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0665","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0670","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.3390\/cancers10060194","article-title":"TGF-\u03b2 in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers."},{"issue":"18","key":"10.1016\/j.blre.2022.100991_bb0675","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"6481","key":"10.1016\/j.blre.2022.100991_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.blre.2022.100991_bb0685","article-title":"Optimizing transplant approaches and post-transplant strategies for patients with acute myeloid Leukemia","volume":"11","author":"Loke","year":"2021","journal-title":"Front Oncol [Internet]"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0690","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2022.100991_bb0695","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies","volume":"54","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.blre.2022.100991_bb0700","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb0705","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia."},{"issue":"13","key":"10.1016\/j.blre.2022.100991_bb0710","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid Leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2022.100991_bb0715","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0720","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2019.227371","article-title":"Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation","volume":"106","author":"Saliba","year":"2021","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0725","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000580","article-title":"Allogeneic stem cell transplantation platforms with ex vivo and in vivo immune manipulations: count and adjust","volume":"5","author":"de Witte","year":"2021","journal-title":"HemaSphere."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0730","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0735","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.bbmt.2015.03.011","article-title":"Dynamical System modeling of immune reconstitution after allogeneic stem cell transplantation identifies patients at risk for adverse outcomes","volume":"21","author":"Toor","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100991_bb0740","first-page":"507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0745","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0750","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbmt.2012.10.010","article-title":"Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children","volume":"19","author":"Bartelink","year":"2013","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0755","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.2020007905","article-title":"CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation","volume":"137","author":"de Koning","year":"2020","journal-title":"Blood [Internet]"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb0760","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41409-018-0351-x","article-title":"Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting","volume":"54","author":"Bondanza","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0765","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bbmt.2014.04.003","article-title":"Increasing chimerism following allogeneic stem cell transplantation is associated with longer survival time","volume":"20","author":"Tang","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0770","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2015.133","article-title":"Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients","volume":"50","author":"Yew","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0775","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm.3100","article-title":"Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation","volume":"19","author":"van Heijst","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0780","first-page":"144","article-title":"Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis","volume":"26","author":"Wang","year":"2021","journal-title":"Hematol Amst Neth"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0785","first-page":"76","article-title":"UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections","volume":"27","author":"Dumont-Lagac\u00e9","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2022.100991_bb0790","first-page":"1295","article-title":"Immune reconstitution in the aging host: opportunities for mechanism-based therapy in allogeneic hematopoietic cell transplantation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0795","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0800","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","article-title":"Haematopoietic stem cell activity and interactions with the niche","volume":"20","author":"Pinho","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"26","key":"10.1016\/j.blre.2022.100991_bb0805","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0810","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb0815","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbmt.2005.08.032","article-title":"Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Reddy","year":"2005","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0820","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1084\/jem.180.1.223","article-title":"B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation","volume":"180","author":"Murphy","year":"1994","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb0825","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.exphem.2016.08.001","article-title":"Immunological properties of bone marrow microenvironment 1 year after allogeneic hematopoietic stem cell transplantation","volume":"44","author":"Ciomber","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100991_bb0830","first-page":"118","article-title":"Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Szyska","year":"2016","journal-title":"Front Immunol [Internet]"},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb0835","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bbmt.2016.04.016","article-title":"Increased Type 1 immune response in the bone marrow immune microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Wang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2022.100991_bb0840","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2007-12-130534","article-title":"Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts","volume":"112","author":"Delisle","year":"2008","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2022.100991_bb0845","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2009-11-253559","article-title":"Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation","volume":"115","author":"Shono","year":"2010","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100991_bb0850","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100991_bb0855","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fimmu.2020.01068","article-title":"Improved relapse-free survival in patients with high natural killer cell doses in grafts and during early immune reconstitution after allogeneic stem cell transplantation","volume":"11","author":"Minculescu","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2022.100991_bb0860","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100991_bb0865","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2020.02022","article-title":"Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0870","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after post-transplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0875","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41375-018-0170-5","article-title":"Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide","volume":"33","author":"Shimoni","year":"2019","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0880","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2021.005","article-title":"Donor KIR3DL1\/receptor HLA-Bw4-80I combination reduces acute leukemia relapse after umbilical cord blood transplantation without in vitro T-cell depletion","volume":"13","author":"Fang","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb0885","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15283\/ijsc18094","article-title":"Predictive role of circulating immune cell subtypes early after allogeneic hematopoietic stem cell transplantation in patients with Acute Leukemia","volume":"12","author":"Kim","year":"2018","journal-title":"Int J Stem Cells"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0890","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.bbmt.2012.01.020","article-title":"Roles of transforming growth factor-\u03b2 in graft-versus-host and graft-versus-tumor effects","volume":"18","author":"Carli","year":"2012","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb0895","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.leukres.2010.03.017","article-title":"Decrease of CD4+CD25+ regulatory T cells and TGF-\u03b2 at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation","volume":"34","author":"Li","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100991_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103991","article-title":"Regulatory T cells in allogeneic hematopoietic stem cell transplantation: from the lab to the clinic","volume":"346","author":"Gu","year":"2019","journal-title":"Cell Immunol"},{"issue":"14","key":"10.1016\/j.blre.2022.100991_bb0905","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0910","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14433","article-title":"Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review","volume":"176","author":"Fisher","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb0915","first-page":"918","article-title":"The impact of graft CD3 cell\/regulatory T cell ratio on acute graft-versus-host disease and post-transplantation outcome: a prospective multicenter study of patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation","volume":"27","author":"Delia","year":"2021","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"10.1016\/j.blre.2022.100991_bb0920","first-page":"1","article-title":"Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation","author":"Tecchio","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0925","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V98.2.489","article-title":"Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation","volume":"98","author":"Storek","year":"2001","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0930","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","article-title":"Elevated numbers of immature\/transitional CD21\u2212 B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease","volume":"14","author":"Greinix","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100991_bb0935","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fimmu.2019.00782","article-title":"B cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children","volume":"10","author":"van der Maas","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb0940","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb0945","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-018-0244-z","article-title":"Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation","volume":"54","author":"Wong","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.blre.2022.100991_bb0950","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100991_bb0955","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun [Internet]"},{"key":"10.1016\/j.blre.2022.100991_bb0960","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0965","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"567","key":"10.1016\/j.blre.2022.100991_bb0970","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb8969","article-title":"Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans","volume":"12","author":"Uhl","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb0975","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.bbmt.2019.01.016","article-title":"Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zeiser","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100991_bb0980","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630429","article-title":"TKI maintenance after stem-Cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis","volume":"12","author":"Gagelmann","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb0985","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.blre.2022.100991_bb0990","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2019000453","article-title":"Pegylated interferon-2\u03b1 invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation","volume":"3","author":"Henden","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.blre.2022.100991_bb0995","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100991_bb1000","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/ijms20010228","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment","volume":"20","author":"Rautenberg","year":"2019","journal-title":"Int J Mol Sci [Internet]"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb1005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.1995.tb08356.x","article-title":"T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor\u2019s peripheral blood lymphocytes for prevention of relapse","volume":"89","author":"Naparstek","year":"1995","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2022.100991_bb1010","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2006.08.034","article-title":"T cell depleted peripheral blood stem cell allotransplantation with T Cell add back for patients with hematological malignancies: effect of chronic GVHD on outcome","volume":"12","author":"Montero","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2022.100991_bb1015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","article-title":"High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen","volume":"19","author":"Liga","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.blre.2022.100991_bb1020","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2019000388","article-title":"Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste","volume":"4","author":"Scott","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb1025","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-020-0798-4","volume":"55","author":"Kothari","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2022.100991_bb1030","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1200\/JCO.2011.41.1116","article-title":"Donor lymphocyte infusion induces polyspecific CD8+ T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100991_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109992","article-title":"Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy","volume":"37","author":"Bachireddy","year":"2021","journal-title":"Cell Rep"},{"issue":"21","key":"10.1016\/j.blre.2022.100991_bb1040","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/bloodadvances.2020004073","article-title":"Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI","volume":"5","author":"Schultze-Florey","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.blre.2022.100991_bb1045","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb1050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.blre.2022.100991_bb1055","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2022.100991_bb1060","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2022.100991_bb1065","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell Transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.blre.2022.100991_bb1070","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.blre.2022.100991_bb1075","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2022.100991_bb1080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1704223","article-title":"Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course","volume":"32","author":"Lee","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2022.100991_bb1085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bmt.1702659","article-title":"Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy","volume":"26","author":"Chong","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.blre.2022.100991_bb1090","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100991_bb1095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2022.100991_bb1100","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.2021010867","article-title":"Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation","volume":"137","author":"Penter","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100991_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.634435","article-title":"The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation","volume":"12","author":"K\u00f6hler","year":"2021","journal-title":"Front Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:05Z","timestamp":1759437005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":221,"alternative-id":["S0268960X22000650"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100991","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100991"}}